Resources for Planning and Conducting Decentralized Clinical Trials
Rapid advances in digital health technologies are fueling a paradigm shift in clinical trial design towards decentralized clinical trials (DCTs), in which research is conducted in part or entirely away from traditional clinical trial sites. The goal of decentralization is to reduce the burden of clinical trial participation, improve recruitment and retention, enroll more participants from groups traditionally underrepresented in research, increase efficiency and allow more frequent, granular measurements in a “real world” setting.
We have compiled resources from regulators and researchers to facilitate the design and conduct of DCTs.
Please bookmark and return to this collection of resources often. The decentralized trial space is rapidly evolving, with additional guidance and resources continuously shared with the research community.
Food and Drug Administration Guidance
The Food and Drug Administration (FDA) plays a key role in guiding decentralized clinical trials by offering non-binding recommendations that help researchers design studies aligned with regulatory standards. These guidance documents support scientific rigor, data integrity, and participant safety across remote and hybrid trial models. For academic teams, they provide a framework to ensure compliance while innovating in trial delivery and access.
